-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
The epigenetic keys to unlocking the full potential of immunotherapy
- Share
- Tweet
- Share on Facebook
- Share
Our White Paper is a deep dive into the science of epigenetics, and its potential to reveal deep insights into how our bodies react and respond to medication during cancer therapy and immunotherapies.
With the rise of novel immunotherapies, there is a need for markers that are able to predict treatment response or ineffectiveness, in order to improve patient outcomes.
Related Articles
- Share
- Tweet
- Share on Facebook
- Share
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields